The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...
B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity and ...
Considering the CLARITY Phase III study results, cladribine tablets may offer several improvements over existing MS drugs including a simple, short-course annual dosing regimen of either 2 or 4 weeks ...
MedPage Today brought together three expert leaders for a virtual roundtable discussion on the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and ...
- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Do not take AUBAGIO if you have severe liver problems, are pregnant or are of childbearing potential and not using effective birth control, have had an allergic reaction to Aubagio or Leflunomide or ...
- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...
The first participant has been dosed in an investigator-led Phase 2 trial testing pegsebrenatide as a potential treatment for ...
Samantha Salvaggio learned she had relapsing-remitting multiple sclerosis (RRMS) in 2005, when she was a 19-year-old sophomore at Ohio State University. Over the next 16 years, she averaged one ...
Hosted on MSN
Multiple sclerosis medication gap: Study finds women less likely than men to receive drugs
Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results